Ross Kerr

Dr. Ross Kerr received his DDS from McGill University in Montreal, Canada, and his MSD and certificate in Oral Medicine at the University of Washington.

He is a Diplomate of the American Board of Oral Medicine and Clinical Professor in the Department of Oral & Maxillofacial Pathology, Radiology & Medicine at New York University College of Dentistry.

Ross Kerr is a past president of the American Academy of Oral Medicine, a steering committee member of the World Workshop on Oral Medicine, a director of the American Board of Oral Medicine, and he serves as a member of the Scientific Advisory Board for the Oral Cancer Foundation.

His research experience includes the evaluation of current and emerging technologies for the early detection of oral cancer. He has lectured nationally and internationally on oral cancer, dry mouth, and other oral medicine related topics, and has contributed to the dental and medical literature. His private practice is focused on the management of patients with oral mucosal diseases, dry mouth, and the dental management of medically complex patients.



Management of the most common oral mucosal diseases (Ross Kerr)

Up to 10% of patients in the adult general population have a mucosal abnormality. Most are benign and cause no symptoms. This talk will focus on how to manage patients who are diagnosed with common mucosal/submucosal diseases, including exophytic lesions, ulcers, red &/or white lesions, and pigmented lesions. Management will include surgical and pharmacological approaches as applicable (including the use of corticosteroids, antivirals, and antifungal agents).


Oral potentially malignant lesions and oral cancer (Ross Kerr)

How many lives have you saved? This talk, with a discussion of cases, will prepare the entire dental team to implement early detection of oral potentially malignant lesions (OPMLs) and oral cancer into their practice. Participants will learn about the current epidemiology, pathogenesis, clinical presentations, and molecular basis for OMPLs and oral cancer, and appreciate what to do when abnormal examination findings are encountered. Also included will be the evidence-based indications for using currently available diagnostic and adjunctive techniques, and management of OPMLs and oral cancer.

Íslandsmót ehf | Suðurlandsbraut 4a | 534 7010 | | kt: 500106-1740

Íslandsmót Ehf. | Suðurlandsbraut 4a | 534 7010 | | kt: 5001061740

Íslandsmót Ehf. | Suðurlandsbraut 4a | 534 7010 | | kt: 5001061740

Íslandsmót Ehf. | Suðurlandsbraut 4a | 534 7010 | | kt: 5001061740